Yang Dongyan, Gao Zhilong, Yang Xuezhu, Gao Liguo
Dongyan Yang, Department of Oncology Three Ward, Renmin Hospital, Hubei University of Medicine, Shiyan 442000, China.
Zhilong Gao, Department of Gastrointestinal Medicine III, Renmin Hospital, Hubei University of Medicine, Shiyan 442000, China.
Pak J Med Sci. 2024 Oct;40(9):2101-2106. doi: 10.12669/pjms.40.9.9049.
Exploring the clinical efficacy and safety of targeted therapy, immunotherapy combined with chemotherapy in the treatment of advanced gastric cancer.
A retrospective analysis was performed on the medical records of 134 patients with advanced gastric cancer who visited Renmin Hospital, Hubei University of Medicine from January 2019 to December 2022. According to therapeutic regimens, enrolled patients were divided into the control group and the study group. Patients in the control group received chemotherapy intervention, while those in the study group were provided with a combined intervention of apatinib, PD-1 inhibitor and chemotherapy. We analyze the tumor control effect and incidence of adverse reactions in two groups of patients.
The disease control rate (DCR) of patients in the study group and the control group was 72.06% and 42.42%, with an overall response rate (ORR) of 8.82% and 4.55%, The differences are statistically significant(P<0.05). By the end of follow-up, the median progression-free survival (mPFS) and the median overall survival (mOS) of the control group patients were 3.0±0.266 and 5.0±0.224 months respectively; while the mPFS and mOS of the study group were 5.0±0.261 and 7.0±0.172 months respectively, the differences are statistically significant (P<0.05). However, there was no significant difference in adverse reactions between the two groups (P>0.05).
The therapeutic regimen of apatinib, a PD-1 inhibitor combined with chemotherapy exhibits relatively high clinical efficacy and safety for the treatment of patients with advanced gastric cancer. It can be considered as an interventional option for this type of patient.
探讨靶向治疗、免疫治疗联合化疗在晚期胃癌治疗中的临床疗效及安全性。
对2019年1月至2022年12月就诊于湖北医药学院附属人民医院的134例晚期胃癌患者的病历进行回顾性分析。根据治疗方案，将入选患者分为对照组和研究组。对照组患者接受化疗干预，研究组患者接受阿帕替尼、PD-1抑制剂联合化疗的综合干预。分析两组患者的肿瘤控制效果及不良反应发生率。
研究组和对照组患者的疾病控制率（DCR）分别为72.06%和42.42%，总缓解率（ORR）分别为8.82%和4.55%，差异有统计学意义（P<0.05）。随访结束时，对照组患者的中位无进展生存期（mPFS）和中位总生存期（mOS）分别为3.0±0.266个月和5.0±0.224个月；而研究组的mPFS和mOS分别为5.0±0.261个月和7.0±0.172个月，差异有统计学意义（P<0.05）。然而，两组之间的不良反应无显著差异（P>0.05）。
阿帕替尼、PD-1抑制剂联合化疗的治疗方案对晚期胃癌患者的治疗具有较高的临床疗效和安全性。可作为这类患者的一种干预选择。
